Dr. Reddy’s Laboratories has launched Palonosetron Hydrochloride Injection, 0.25 mg (base)/ 5 mL, a therapeutic equivalent generic version of ALOXI (palonosetron hydrochloride) Injection approved by the US Food and Drug Administration (USFDA).
The ALOXI brand and generic had US sales of around $446 million MAT for the most recent twelve months ending in January 2018 according to IMS Health.
Dr. Reddy’s Palonosetron Hydrochloride Injection is available in strength of 0.25 mg/5 mL (free base) in a single-dose vial packaged in a carton containing one vial.
ALOXI is a registered trademark of Helsinn Healthcare SA.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
